Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T15:35:40.458Z.
Calculation as of: 2026-10-06T15:35:40.458Z.
Quote observation: 2026-10-06T15:34:50.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a5b8a39003d923715743cc0d1a2c59dcf36f227505f31b08d3d275f4059bcabd
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Attovia Therapeutics, Inc.
Market Cap
$780.99M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$770.72M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$770.55M
Free Cash Flow Yield
6.86%
TTM Avg
7.62%
3Y Avg
7.21%
5Y Avg
5.53%
Market Cap
$787.12M
Free Cash Flow Yield
N/A
TTM Avg
46.69%
3Y Avg
46.69%
5Y Avg
28.31%
Market Cap
$795.58M
Free Cash Flow Yield
12.28%
TTM Avg
14.50%
3Y Avg
12.95%
5Y Avg
8.98%
Market Cap
$790.35M
Free Cash Flow Yield
N/A
TTM Avg
1.71%
3Y Avg
1.71%
5Y Avg
1.71%
Market Cap
$796.03M
Free Cash Flow Yield
N/A
TTM Avg
0.32%
3Y Avg
2.22%
5Y Avg
3.37%
Market Cap
$752.87M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$805.59M
Free Cash Flow Yield
10.86%
TTM Avg
10.11%
3Y Avg
10.17%
5Y Avg
7.95%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | $780.99M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $770.72M | N/A | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $770.55M | 6.86% | 7.62% | 7.21% | 5.53% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $787.12M | N/A | 46.69% | 46.69% | 28.31% |
| AdaptHealth Corp. (AHCO)vs › | $795.58M | 12.28% | 14.50% | 12.95% | 8.98% |
| Geron Corporation (GERN)vs › | $790.35M | N/A | 1.71% | 1.71% | 1.71% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $796.03M | N/A | 0.32% | 2.22% | 3.37% |
| Candel Therapeutics, Inc. (CADL)vs › | $752.87M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $805.59M | 10.86% | 10.11% | 10.17% | 7.95% |
| Apnimed, Inc. (APMD)vs › | $807.61M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
